{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:33:58Z","timestamp":1793734438189,"version":"4.6.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,2,7]],"date-time":"2011-02-07T00:00:00Z","timestamp":1297036800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1471-2377-11-21","type":"journal-article","created":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T07:15:33Z","timestamp":1297149333000},"source":"Crossref","is-referenced-by-count":50,"title":["Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology"],"prefix":"10.1186","volume":"11","author":[{"given":"Marwan","family":"Sabbagh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,7]]},"reference":[{"key":"568_CR1","unstructured":"Alzheimer's Association: 2010 Alzheimer's disease facts and figures. Alzheimer's Association web site. Accessed September 22, 2010, [ http:\/\/www.alz.org\/documents_custom\/report_alzfactsfigures2010.pdf ]"},{"issue":"8","key":"568_CR2","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1001\/archneur.60.8.1119","volume":"60","author":"LE Hebert","year":"2003","unstructured":"Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA: Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003, 60 (8): 1119-1122. 10.1001\/archneur.60.8.1119.","journal-title":"Arch Neurol"},{"key":"568_CR3","unstructured":"Aricept [package insert]. 2006, Teaneck, NJ: Eisai Inc"},{"key":"568_CR4","unstructured":"Namenda [package insert]. 2007, St. Louis, MO: Forest Laboratories Inc"},{"issue":"6150","key":"568_CR5","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1136\/bmj.2.6150.1457","volume":"2","author":"EK Perry","year":"1978","unstructured":"Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J. 1978, 2 (6150): 1457-1459. 10.1136\/bmj.2.6150.1457.","journal-title":"Br Med J"},{"issue":"Spec No 2","key":"568_CR6","doi-asserted-by":"publisher","first-page":"S160","DOI":"10.1259\/bjr\/97295129","volume":"80","author":"K Herholz","year":"2007","unstructured":"Herholz K, Carter SF, Jones M: Positron emission tomography imaging in dementia. Br J Radiol. 2007, 80 (Spec No 2): S160-S167. 10.1259\/bjr\/97295129.","journal-title":"Br J Radiol"},{"issue":"9068","key":"568_CR7","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/S0140-6736(96)09124-6","volume":"349","author":"M Iyo","year":"1997","unstructured":"Iyo M, Namba H, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, Sudo Y, Suzuki K, Irie T: Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet. 1997, 349 (9068): 1805-1809. 10.1016\/S0140-6736(96)09124-6.","journal-title":"Lancet"},{"issue":"3","key":"568_CR8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/1531-8249(200009)48:3<391::AID-ANA17>3.0.CO;2-H","volume":"48","author":"DE Kuhl","year":"2000","unstructured":"Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA: Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol. 2000, 48 (3): 391-395. 10.1002\/1531-8249(200009)48:3<391::AID-ANA17>3.0.CO;2-H.","journal-title":"Ann Neurol"},{"issue":"1-2","key":"568_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.neulet.2005.01.031","volume":"380","author":"NI Bohnen","year":"2005","unstructured":"Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti B, Davis JG, Constantine G, Mathis CA, Moore RY, DeKosky ST: Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neurosci Lett. 2005, 380 (1-2): 127-132. 10.1016\/j.neulet.2005.01.031.","journal-title":"Neurosci Lett"},{"issue":"1","key":"568_CR10","first-page":"27","volume":"23","author":"H Hanyu","year":"2002","unstructured":"Hanyu H, Asano T, Sakurai H, Tanaka Y, Takasaki M, Abe K: MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia. AJNR Am J Neuroradiol. 2002, 23 (1): 27-32.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"Pt 11","key":"568_CR11","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1093\/brain\/awh589","volume":"128","author":"SJ Teipel","year":"2005","unstructured":"Teipel SJ, Flatz WH, Heinsen H, Bokde AL, Schoenberg SO, Stockel S, Dietrich O, Reiser MF, Moller HJ, Hampel H: Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain. 2005, 128 (Pt 11): 2626-2644. 10.1093\/brain\/awh589.","journal-title":"Brain"},{"issue":"25","key":"568_CR12","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.2174\/1381612043383331","volume":"10","author":"DK Lahiri","year":"2004","unstructured":"Lahiri DK, Rogers JT, Greig NH, Sambamurti K: Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. Curr Pharm Des. 2004, 10 (25): 3111-3119. 10.2174\/1381612043383331.","journal-title":"Curr Pharm Des"},{"issue":"Suppl 13","key":"568_CR13","first-page":"19","volume":"59","author":"PJ Whitehouse","year":"1998","unstructured":"Whitehouse PJ: The cholinergic deficit in Alzheimer's disease. J Clin Psychiatry. 1998, 59 (Suppl 13): 19-22.","journal-title":"J Clin Psychiatry"},{"issue":"15","key":"568_CR14","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/jama.281.15.1401","volume":"281","author":"KL Davis","year":"1999","unstructured":"Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V: Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999, 281 (15): 1401-1406. 10.1001\/jama.281.15.1401.","journal-title":"JAMA"},{"issue":"4","key":"568_CR15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/00002093-200010000-00006","volume":"14","author":"JJ Sramek","year":"2000","unstructured":"Sramek JJ, Cutler NR: RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy?. Alzheimer Dis Assoc Disord. 2000, 14 (4): 216-227. 10.1097\/00002093-200010000-00006.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"10","key":"568_CR16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2165\/00003088-200241100-00003","volume":"41","author":"MW Jann","year":"2002","unstructured":"Jann MW, Shirley KL, Small GW: Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002, 41 (10): 719-739. 10.2165\/00003088-200241100-00003.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"568_CR17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/00004714-200212000-00012","volume":"22","author":"V Kaasinen","year":"2002","unstructured":"Kaasinen V, Nagren K, Jarvenpaa T, Roivainen A, Yu M, Oikonen V, Kurki T, Rinne JO: Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol. 2002, 22 (6): 615-620. 10.1097\/00004714-200212000-00012.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"568_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1159\/000122961","volume":"25","author":"A Homma","year":"2008","unstructured":"Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, Takita M, Arimoto I, Koma H, Ohbayashi T: Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord. 2008, 25 (5): 399-407. 10.1159\/000122961.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"7","key":"568_CR19","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/gps.1133","volume":"19","author":"A Whitehead","year":"2004","unstructured":"Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG: Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry. 2004, 19 (7): 624-633. 10.1002\/gps.1133.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"2","key":"568_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1479-8301.2009.00291.x","volume":"9","author":"M Nozawa","year":"2009","unstructured":"Nozawa M, Ichimiya Y, Nozawa E, Utumi Y, Sugiyama H, Murayama N, Iseki E, Arai H: Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan. Psychogeriatrics. 2009, 9 (2): 50-55. 10.1111\/j.1479-8301.2009.00291.x.","journal-title":"Psychogeriatrics"},{"issue":"3","key":"568_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000017126","volume":"10","author":"A Burns","year":"1999","unstructured":"Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT: The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord. 1999, 10 (3): 237-244. 10.1159\/000017126.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"9","key":"568_CR22","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/archinte.158.9.1021","volume":"158","author":"SL Rogers","year":"1998","unstructured":"Rogers SL, Doody RS, Mohs RC, Friedhoff LT, the Donepezil Study Group: Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998, 158 (9): 1021-1031. 10.1001\/archinte.158.9.1021.","journal-title":"Arch Intern Med"},{"issue":"1","key":"568_CR23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1212\/WNL.50.1.136","volume":"50","author":"SL Rogers","year":"1998","unstructured":"Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, Donepezil Study Group: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998, 50 (1): 136-145.","journal-title":"Neurology"},{"issue":"2","key":"568_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2165\/00002512-200825020-00008","volume":"25","author":"RS Doody","year":"2008","unstructured":"Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R: Safety and tolerability of donepezil at doses up to 20 mg\/day: results from a pilot study in patients with Alzheimer's disease. Drugs Aging. 2008, 25 (2): 163-174. 10.2165\/00002512-200825020-00008.","journal-title":"Drugs Aging"},{"issue":"7","key":"568_CR25","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.clinthera.2010.06.019","volume":"32","author":"MR Farlow","year":"2010","unstructured":"Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A: Effectiveness and tolerability of high-dose (23 mg\/d) versus standard-dose (10 mg\/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther. 2010, 32 (7): 1234-1251. 10.1016\/j.clinthera.2010.06.019.","journal-title":"Clin Ther"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-11-21.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2377-11-21\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-11-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T00:24:56Z","timestamp":1468283096000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/1471-2377-11-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["568"],"URL":"https:\/\/doi.org\/10.1186\/1471-2377-11-21","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,7]]},"article-number":"21"}}